#125897
#125898
Re: Farmas USA
TgTX
Datos positivos en esclerosis múltiple. Enhorabuena a los premiados del lugar.
Cumple objetivo principal:
significant reduction in annualized relapse rate (ARR) over a 96-week period (p<0.005 in each trial).
https://seekingalpha.com/news/3643233-tg-therapeutics-soars-23-on-positive-ublituximab-data-in-multiple-sclerosis
Datos positivos en esclerosis múltiple. Enhorabuena a los premiados del lugar.
Cumple objetivo principal:
significant reduction in annualized relapse rate (ARR) over a 96-week period (p<0.005 in each trial).
https://seekingalpha.com/news/3643233-tg-therapeutics-soars-23-on-positive-ublituximab-data-in-multiple-sclerosis
«Después de nada, o después de todo/ supe que todo no era más que nada.»
#125899
Re: Farmas USA
Framus, más vidas aún de TGTX !! Por fin, 5 años con ella
LOL
LOL
TG Therapeutics soars 23% on positive ublituximab data in multiple sclerosis
- TG Therapeutics (NASDAQ:TGTX) jumps 23% premarket on positive topline resultsfrom two global, Phase 3 studies, called ULTIMATE I & ULTIMATE II, evaluating ublituximab, an investigational, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide in patients with relapsing forms of multiple sclerosis (RMS).
- The ULTIMATE I & II trials enrolled a total of 1,094 patients. Both studies met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) over a 96-week period (p<0.005 in each trial).
- Ublituximab resulted in an ARR of <0.10 in each of ULTIMATE studies, with a relative reduction in ARR of ~60% and 50%, respectively, over teriflunomide.
- Further analyses of both the studies including safety and secondary endpoints will be presented at an upcoming medical congress, targeted in H1 2021.
- Additionally, data from these studies are intended to support a BLA submission for ublituximab in RMS targeted in mid-year 2021.
- The company will host a conference call today at 8:30 AM ET to discuss the ULTIMATE I & II topline results.
#125900
Re: Farmas USA
Gilead Sciences to Acquire MYR GmbH
#125901
Re: Farmas USA
ONCT ahí lo tenemos, no han tardado eh! :P, enga, ya estamos financiados para 2022 o más!
a 4,5$ la han valorado
Dec-09-20 11:50PM | Oncternal Therapeutics Increases Previously Announced Bought Deal to $75.0 Million GlobeNewswire
06:08PM | Oncternal Therapeutics Announces $40.0 Million Bought Deal Offering GlobeNewswire
a 4,5$ la han valorado
Dec-09-20 11:50PM | Oncternal Therapeutics Increases Previously Announced Bought Deal to $75.0 Million GlobeNewswire
06:08PM | Oncternal Therapeutics Announces $40.0 Million Bought Deal Offering GlobeNewswire
#125902
Re: Farmas USA
KPTI
Muchas gracias, tengo orden de compra en 15.00.
Muchas gracias, tengo orden de compra en 15.00.
#125903
Re: Farmas USA
ONCT
Vaya truño de acuerdo. Ha vuelto a $4.5. Y BO de otro Ror1.
https://twitter.com/sentivcapital/status/1336618539856310275?s=19
He añadido unas pocas a $4.61 en pm
Vaya truño de acuerdo. Ha vuelto a $4.5. Y BO de otro Ror1.
https://twitter.com/sentivcapital/status/1336618539856310275?s=19
He añadido unas pocas a $4.61 en pm
#125904
Re: Farmas USA
Este va a ser el siguiente ROR1 que se va a vender